Boston Scientific Obtains CE Mark For ACURATE Prime Aortic Valve System, The Newest Transcatheter Aortic Valve Replacement Technology In Structural Heart Portfolio
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific has received the CE Mark for its ACURATE Prime Aortic Valve System, a new transcatheter aortic valve replacement technology. This addition enhances their structural heart portfolio.
August 27, 2024 | 10:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific has obtained the CE Mark for its ACURATE Prime Aortic Valve System, indicating regulatory approval in Europe. This development is likely to enhance their product offerings in the structural heart market.
The CE Mark approval allows Boston Scientific to market the ACURATE Prime Aortic Valve System in Europe, potentially increasing sales and market share in the structural heart segment. This regulatory milestone is a positive indicator for the company's growth in the medical device sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100